Abstract
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers In a Phase 1 trial, patients with refractory lymphoid cancers, an antibody-drug complex directed against ROR1 had no unexpected toxicities. About half of the patients with mantle cell lymphoma and diffuse large B-cell lymphoma had clinically meaningful responses.
MeSH terms
-
Humans
-
Immunoconjugates / pharmacology
-
Immunoconjugates / therapeutic use
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Mantle-Cell* / drug therapy
-
Receptor Tyrosine Kinase-like Orphan Receptors* / metabolism
Substances
-
Receptor Tyrosine Kinase-like Orphan Receptors
-
ROR1 protein, human
-
Immunoconjugates